RxDoctor Payments Data

Islam Othman, MD

Interventional Cardiology · Raleigh, NCNPI 1700905411

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $30,500 of the $49,760 with a category attached, or 61.3%. Boston Scientific accounts for 88.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $29,896 and has fallen 95.4% since, to $1,388 in 2025.

$49,760in general payments, 2019–2025

Across 87 payments — averaging $571.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$44K
  • Bayer$4K
  • Philips North America LLC$1K
  • Amgen$97
  • Asahi Intecc USA, Inc.$70
  • Teleflex LLC$53
  • plus $186 from 6 others
$23,927in research payments, 2019–2025

Across 7 payments — averaging $3418.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$13K
  • Intact Vascular, Inc.$10K

What the payments were for

  • Consulting fees$7,60015%
  • Speaking & faculty fees$30,50061%
  • Travel & lodging$8,29317%
  • Food & beverage$3,3667%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,760 in reported general payments places this provider in the 85th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$136,096
Medicare patients
373
Services billed
1,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban201$228,420
Repatha SureclickEvolocumab62$56,981
XareltoRivaroxaban49$44,120
EntrestoSacubitril/Valsartan29$36,795
JardianceEmpagliflozin20$22,497
BrilintaTicagrelor12$7,484
Metoprolol Succinate180$2,778
Rosuvastatin Calcium143$1,906
Carvedilol184$1,527
Atorvastatin Calcium151$1,410
Losartan Potassium114$1,167
Ranolazine ErRanolazine16$1,066
ClopidogrelClopidogrel Bisulfate94$993
Lisinopril112$835
Hydralazine Hcl39$687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$228,420201 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →